University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics, Groningen, NL.
Center for Medicines Information and Pharmaceutical Care, Faculty of Pharmacy, Universitas Surabaya, Surabaya, ID.
Glob Heart. 2020 Feb 6;15(1):8. doi: 10.5334/gh.394.
Acute ST-elevation myocardial infarction (STEMI) is a potentially fatal presentation of coronary artery disease (CAD). Evidence of the impact of acute pharmacological interventions in non-reperfused STEMI patients on subsequent events is limited. We aimed to assess the association between adherence to guideline-recommended preventive medications and in-hospital mortality among this high-risk patient population.
We conducted a cohort study using data obtained from the Jakarta Acute Coronary Syndrome (JAC) Registry database from a tertiary care academic hospital in Indonesia. We included 1132 of 2694 patients with STEMI recorded between 1 January 2014 and 31 December 2016 who did not undergo acute reperfusion therapy. Adherence to guideline-recommended preventive medications was defined as the combined administration of aspirin, clopidogrel, anticoagulants and statins after hospital admission. The main outcome measure was in-hospital mortality.
Overall, 778 of 1132 patients (69%) received the combination of preventive medications. The guideline non-adherent group had significantly more patients with earlier onset of STEMI, higher Killip class and thrombolysis in myocardial infarction (TIMI) score. After adjustments for measured characteristics using logistic regression modeling, exposure to the combination of preventive therapies was associated with a statistically significant lower risk for in-hospital mortality (adjusted odds ratio: 0.46, 95% confidence interval: 0.30-0.70).
Adherence to guideline-recommended preventive medications was associated with lower risk of in-hospital mortality in non-reperfused STEMI patients. The predictors of not receiving these medications need to be confirmed in future research.
急性 ST 段抬高型心肌梗死(STEMI)是冠状动脉疾病(CAD)的一种潜在致命表现。关于急性药物干预对未再灌注 STEMI 患者后续事件影响的证据有限。我们旨在评估该高危患者人群中,遵循指南推荐的预防药物与住院死亡率之间的相关性。
我们使用来自印度尼西亚一家三级护理学术医院的雅加达急性冠状动脉综合征(JAC)登记数据库中的数据进行了队列研究。我们纳入了 2014 年 1 月 1 日至 2016 年 12 月 31 日期间记录的未进行急性再灌注治疗的 2694 例 STEMI 患者中的 1132 例。入院后接受阿司匹林、氯吡格雷、抗凝剂和他汀类药物联合治疗定义为遵循指南推荐的预防药物。主要观察指标为住院死亡率。
总体而言,1132 例患者中有 778 例(69%)接受了联合预防药物治疗。指南不依从组的患者 STEMI 发病时间更早,Killip 分级和心肌梗死溶栓治疗(TIMI)评分更高。在使用逻辑回归模型对测量特征进行调整后,暴露于联合预防治疗与住院死亡率显著降低相关(调整后的优势比:0.46,95%置信区间:0.30-0.70)。
在未再灌注 STEMI 患者中,遵循指南推荐的预防药物与降低住院死亡率相关。需要在未来的研究中进一步证实未接受这些药物的预测因素。